Navigation Links
Pharmathene Announces Publication of Phase I Study Results for Anthrax Anti-toxin Valortim®
Date:12/6/2011

ANNAPOLIS, Md., Dec. 6, 2011 /PRNewswire/ -- PharmAthene, Inc. (NYSE Amex: PIP) today announced that results from a Phase I clinical study of Valortim® were published in the December issue of Clinical and Vaccine Immunology.  The American Society for Microbiology peer-reviewed journal describes clinical data supporting the potential use of Valortim®, a fully human monoclonal antibody, as both a post-exposure prophylaxis and therapeutic treatment for anthrax infection.

"There is a strong need for additional therapeutic options for inhalational anthrax disease as current therapies, specifically antibiotics and aggressive supportive care, are not optimally effective in individuals with active, symptomatic anthrax infection. Anti-toxin therapies like Valortim® could potentially provide important protection in the event of a bioterrorism attack with anthrax," remarked Dr. Thomas Fuerst, Executive Vice President and Chief Scientific Officer.  "Our Phase I results demonstrate that a single dose of Valortim® can provide  levels of antibodies in humans that correspond to protective levels in animal models and is well tolerated.  Based on the accumulating human safety and animal efficacy data for Valortim®, we believe that it could represent an important addition to the nation's anthrax armamentarium."

Preclinical studies suggest that Valortim® has the potential to provide significant protection against anthrax infection when administered prophylactically (prior to the emergence of symptoms of anthrax infection) and also may increase survival when administered therapeutically (once symptoms become evident).  In these studies, Valortim® has been shown to protect both rabbits and monkeys against the lethal effects of anthrax infection
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. PharmAthene to Present at the Piper Jaffray 23rd Annual Healthcare Conference on November 30, 2011
2. PharmAthene to Present at the 2011 Chemical and Biological Defense Science and Technology Conference
3. PharmAthene to Host Third Quarter 2011 Conference Call and Webcast on Wednesday, November 9, 2011
4. PharmAthene Submits Legal Brief in Response to SIGA Technologies Motion for Reargument
5. PharmAthene Awarded 50% Profit Split on Worldwide Sales of Smallpox Antiviral Therapy by Delaware Chancery Court
6. PharmAthene Announces $6.5 Million Registered Direct Offering
7. PharmAthene Completes Dosing in Valortim® Phase I Clinical Trial
8. PharmAthene Provides Update on Litigation With SIGA Technologies
9. PharmAthene Presents New Anthrax Data at the 5th Annual PHEMCE Stakeholders Workshop and BARDA Industry Day
10. PharmAthene to Host Third Quarter 2010 Conference Call and Webcast on Thursday, November 11, 2010
11. PharmAthene Announces Closing of $15 Million Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... LAVAL, Quebec , Jan. 15, 2014  Valeant Pharmaceuticals ... VRX) announced that the applicable waiting period under the ... to the previously announced tender offer by its indirect ... the outstanding shares of common stock of Solta Medical, ...
(Date:1/14/2014)... 2014 HeartWare International, Inc . (NASDAQ: ... miniaturized circulatory support technologies that are revolutionizing the treatment ... revenues for the fourth quarter of 2013 will be ... approximately $208 million. "Our full-year revenue growth ...
(Date:1/14/2014)... , Jan. 14, 2014 /PRNewswire-iReach/ -- Acumed,s new ... targeting guide with accompanying instrumentation to place and insert ... to the soft tissue (e.g. ligament) repair or reconstruction ... repair heals. (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3
... Mass.--(BUSINESS WIRE)--Jul 3, 2007 - EPIX,Pharmaceuticals, Inc. (NASDAQ:EPIX) ... executive officer of EPIX, is,scheduled to present at ... Tuesday, July 10, 2007 at 1:30 p.m.,(EDT) at ... The presentation will be webcast live and can ...
... DIEGO--(BUSINESS WIRE)--Jul 2, 2007 - Accelrys, Inc.,(NASDAQ:ACCL), the ... announced today that its CFO,Rick Russo, will present ... in New York on July 11, 2007 at,10:30 ... the Mandarin,Oriental Hotel July 10th-12th. In attendance will ...
Cached Medicine Technology:EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin,Emerging Growth Opportunities Conference 2Accelrys to Present to Investors at C.E. Unterberg Emerging Growth,Opportunities Conference 2
(Date:4/23/2014)... A novel compound that targets an important brain receptor ... addiction behaviors, including relapse behavior, a University at Buffalo ... evidence that this may be a novel lead compound ... exist., The UB research was published as an online ... In the study, the compound, RO5263397, severely blunted a ...
(Date:4/23/2014)... April 23, 2014Men whose testosterone falls below normal levels ... be overweight and have heart disease and type 2 ... testosterone-deficient men for further testing and possible treatment is ... Health , a peer-reviewed publication from Mary Ann Liebert, ... Journal of Men,s Health website at ...
(Date:4/23/2014)... and accessible detection methods that can rapidly screen ... a single cell inside that population has been ... Lu. , In the Royal Society of Chemistry ... that he and his coworkers have developed a ... a protein ( Chem. Sci. , 2014, DOI: ...
(Date:4/23/2014)... benefits of probiotics, antioxidants and other nutritional compounds, more ... industry is getting in on the action. But legitimate ... the industry is responding with clinical research to shore ... Chemical & Engineering News (C&EN), the weekly ... M. Bomgardner, a senior editor at C&EN, writes that ...
(Date:4/23/2014)... Ill. - In a country as wealthy as the United ... 12 seniors do not have access to adequate food due ... food insecure. , Recent research at the University of ... Survey (NHANES) revealed that the seniors who are dealing with ... , "In 2011, 8.35 percent of Americans over age 60 ...
Breaking Medicine News(10 mins):Health News:Novel compound halts cocaine addiction and relapse behaviors 2Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2Health News:More Americans in their golden years are going hungry 2
... be common in tropical countries along with the ... researchers in Houston, Texas whose study was published in ... available online. ,Staphylococcus aureus, or staph, ... in the nose of a quarter to a third ...
... the caregiver to a 12-year-old autistic boy who fell to ... being charged with the boy's// death. This despite the police ... his death. ,The boy's name has never been ... not say if they were reopening the case or what ...
... potent herbs, has now uncorked a new product: herbal wine. ... Thapa, a resident of tourist town Pokhara in western Nepal, ... ,For many families, alcohol is an integral part of ... local liquors thrive in Nepal's markets along with foreign beers, ...
... between overweight and infertility in women is well known, but ... the case of obese men.//, ,New research has ... that a man’s chances of getting infertile are enhanced by ... during the four years prior to participating in the study ...
... develop symptoms like chest pain or breathlessness almost 2 hours ... death victims were already at a risk as they had ... prevent sudden cardiac death can be made by learning to ... ,"Our study suggests that shifting the focus to educating ...
... often than biologists once thought. Cutting and rearrangement of the ... by// the human cells. ,The immune system of ... could also help researchers understand better how the immune system ... ,Depending on the specific type of protein required, an ...
Cached Medicine News:Health News:MRSA Linked with Rise in Bacterial Infections 2Health News:Nepal Uncorks 'Herbal Wine' 2Health News:Symptoms develop long before the 'Sudden' Cardiac Death 2Health News:'Mix and match' of proteins may have a significant role in immunity 2
Micro suture forceps....
30 Degree angle....
Operating microscope with motorized zoom and variable focus up to 405 mm....
Advanced operating microscope with zoom and variable focus up to 500 mm....
Medicine Products: